Medicenna Therapeutics Reports Q2 2026 Results and Announces Key Developments in Superkine Programs

Medicenna Therapeutics Corp ( (TSE:MDNA) ) has issued an update.

Medicenna Therapeutics Corp announced its second quarter fiscal 2026 financial results and provided a corporate update, highlighting significant advancements in its Superkine programs. The company is set to present updated clinical data for MDNA11 at the ESMO Immuno-Oncology Congress and is launching a new clinical trial in Italy to evaluate MDNA11 in combination with checkpoint inhibitors for melanoma. Additionally, Medicenna is advancing its MDNA113 bispecific program and has strengthened its patent portfolio, which underscores its commitment to pioneering innovative therapies in oncology.

The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.

Spark’s Take on TSE:MDNA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.

Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.

To see Spark’s full report on TSE:MDNA stock, click here.

More about Medicenna Therapeutics Corp

Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing Superkines targeting cancer, autoimmune, and inflammatory diseases.

Average Trading Volume: 65,944

Technical Sentiment Signal: Buy

Current Market Cap: C$94.84M

Find detailed analytics on MDNA stock on TipRanks’ Stock Analysis page.